- Details
- Alicia Morgans and Christopher Sweeney discuss the IMbassador250 trial results presented at the AACR 2020 virtual meeting. IMbassador250 is a phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone. Dr. Sweeney says that the study conclusively showed that adding atezolizumab to enzalutamide after abirat...
|
- Details
- Alicia Morgans and Charles Ryan highlight the breaking news that the Food and Drug Administration (FDA) approved the first PARP Inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-res...
|
- Details
- The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) (NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Oliver Sartor, the primary author joins Alicia Morgans to provide an update on the PROCEED registry aiming to understand outcomes for Afr...
|
- Details
- In an area where we have multiple options for treatment and we continue to have more data that helps to guide us, Evan Yu joins Alicia Morgans to speak about systemic treatment sequencing in the metastatic castration-resistant prostate cancer (mCRPC) setting and his approach to moving a patient through the different phases of their treatment. Biographies: Evan Yu, MD, Medical oncologist, treats pr...
|
- Details
- Alicia Morgans and Neal Shore discuss the clinical implications of the CARD study, a phase 4 study demonstrating the first third-line treatment for metastatic castration-resistant prostate cancer (mCRPC), that prolonged overall survival with cabazitaxel as compared to treatment with a second AR targeted agent in men who had docetaxel and the alternative AR targeted agent in their prior treatment h...
|
- Details
- In this discussion on the CARD trial with Alicia Morgans, Karim Fizazi discusses the study design, rationale, treatment strategy, and quality of life endpoints from the ASCO GU 2020 presentation: Pain Response and Health-Related Quality of Life Analysis in Patients with Metastatic Castration-Resistant Prostate Cancer from the CARD study. The objective of the QoL analysis was focused on three parti...
|
- Details
- Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...
|
- Details
- Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) specifically, sacituzumab govitecan in metastatic urothelial cancer and the and the initial results from TROPHY-U-01. Although immune checkpoint inhibitors now provide an...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Oliver Sartor and Michael Morris join Charles to discuss lutetium in advanced prostate cancer and the VISION trial. Dr. Michael Morris serves on the scientific oversight committee of the trial, and Dr. Sartor is one of the co-PIs of this clinical trial. The VISION trial has the potential to change clinical practice in the...
|
- Details
- In this conversation, Alicia Morgans and Cora Sternberg, Medical Oncologist and Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine in New York discuss the recently presented results from the CARD trial. The CARD Trial a phase 4 clinical trial compared cabazitaxel vs abiraterone or enzalutamide in patients who were previously treated with docetaxel and had p...
|
